Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Neuroblastoma Treatment Market: By Diagnostics, By Drugs, By Treatment, and Geography
Neuroblastoma Treatment Market: By Diagnostics, By Drugs, By Treatment, and Geography
Neuroblastoma Treatment Market size was valued at US$ 542 billion in 2023 and is poised to grow at a CAGR of 3.6% from 2024-30. The global market provides a detailed overview and that can be segmented by diagnostics, by drugs, and by treatment. By diagnostics, the global neuroblastoma treatment market has been segmented into MIBG Scan, Imaging, Urine Analysis, and Biopsy. The Imaging segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. MIBG scan segment is also growing at a faster rate. Based on drugs, the global neuroblastoma treatment market is segmented Crizotinib, Doxorubicin Hydrochloride, Cyclophosphamide, Vincristine Sulfate, and Others.
Among these, the Crizotinib segment is expected to have the fastest-growing market during the forecast period 2022-2028. It is attributed to the efficiency of the drug and high demand in the market. Also, Hydrochloride drugs has high demand in the global market and is expected to grow at a significant CAGR in the upcoming forecasted years. Based on treatment, the global neuroblastoma treatment market is segmented into Surgery, Chemotherapy, High-Dose Chemotherapy with Stem Cells Support, Monoclonal Antibody Treatment, Radiotherapy, and Others. The Surgery segment accounts for the largest share in 2021.
Chemotherapy segment is the second-largest share during the forecast period 2022-2028 according to precision business insights. Although, high risk and side effects associated with Chemotherapy is restraining the growth of this segment at a significant rate. Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global neuroblastoma treatment products.
Study Period
2024-2030Base Year
2023CAGR
3.6%Largest Market
North AmericaFastest Growing Market
Europe
Increasing prevalence of neuroblastoma, rising healthcare expenses, and a greater number of awareness programs on neuroblastoma are anticipated to propel the market growth over the forecast years.
By region, the North America is expected to witness the highest market share during the forecast period it holds a tremendous potential market for global neuroblastoma treatment.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 542 billion |
|
Market CAGR |
3.6% |
|
By Diagnostics |
|
|
By Drugs |
|
|
By Treatment |
|
|
By Region |
|
Download Free Sample Report
The global neuroblastoma treatment market size was valued at US$ 542 billion in 2023 and is projected to grow at a CAGR of 3.6% from 2024-2030.
Investment in research and development sector to invent new therapies and treatment are the main strategy of the global market players.
High cost and side effects associated with treatment options may hamper the global market growth.
| 1.Executive Summary |
| 2.Global Neuroblastoma Treatment Market Introduction |
| 2.1.Global Neuroblastoma Treatment Market - Taxonomy |
| 2.2.Global Neuroblastoma Treatment Market - Definitions |
| 2.2.1.Diagnostics |
| 2.2.2.Drugs |
| 2.2.3.Treatment |
| 2.2.4.Region |
| 3.Global Neuroblastoma Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Neuroblastoma Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Neuroblastoma Treatment Market By Diagnostics, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. MIBG Scan |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Imaging |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Urine Analysis |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Biopsy |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Neuroblastoma Treatment Market By Drugs, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Crizotinib |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Doxorubicin Hydrochloride |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Cyclophosphamide |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Vincristine Sulfate |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Neuroblastoma Treatment Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Surgery |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Chemotherapy |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. High-Dose Chemotherapy with Stem Cell Support |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Monoclonal Antibody Treatment |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Radiotherapy |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Others |
| 7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 8.Global Neuroblastoma Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Neuroblastoma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Diagnostics Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.MIBG Scan |
| 9.1.2.Imaging |
| 9.1.3.Urine Analysis |
| 9.1.4.Biopsy |
| 9.2. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Crizotinib |
| 9.2.2.Doxorubicin Hydrochloride |
| 9.2.3.Cyclophosphamide |
| 9.2.4.Vincristine Sulfate |
| 9.2.5.Others |
| 9.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Surgery |
| 9.3.2.Chemotherapy |
| 9.3.3.High-Dose Chemotherapy with Stem Cell Support |
| 9.3.4.Monoclonal Antibody Treatment |
| 9.3.5.Radiotherapy |
| 9.3.6.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Neuroblastoma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Diagnostics Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.MIBG Scan |
| 10.1.2.Imaging |
| 10.1.3.Urine Analysis |
| 10.1.4.Biopsy |
| 10.2. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Crizotinib |
| 10.2.2.Doxorubicin Hydrochloride |
| 10.2.3.Cyclophosphamide |
| 10.2.4.Vincristine Sulfate |
| 10.2.5.Others |
| 10.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Surgery |
| 10.3.2.Chemotherapy |
| 10.3.3.High-Dose Chemotherapy with Stem Cell Support |
| 10.3.4.Monoclonal Antibody Treatment |
| 10.3.5.Radiotherapy |
| 10.3.6.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Neuroblastoma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Diagnostics Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.MIBG Scan |
| 11.1.2.Imaging |
| 11.1.3.Urine Analysis |
| 11.1.4.Biopsy |
| 11.2. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Crizotinib |
| 11.2.2.Doxorubicin Hydrochloride |
| 11.2.3.Cyclophosphamide |
| 11.2.4.Vincristine Sulfate |
| 11.2.5.Others |
| 11.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Surgery |
| 11.3.2.Chemotherapy |
| 11.3.3.High-Dose Chemotherapy with Stem Cell Support |
| 11.3.4.Monoclonal Antibody Treatment |
| 11.3.5.Radiotherapy |
| 11.3.6.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Neuroblastoma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Diagnostics Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.MIBG Scan |
| 12.1.2.Imaging |
| 12.1.3.Urine Analysis |
| 12.1.4.Biopsy |
| 12.2. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Crizotinib |
| 12.2.2.Doxorubicin Hydrochloride |
| 12.2.3.Cyclophosphamide |
| 12.2.4.Vincristine Sulfate |
| 12.2.5.Others |
| 12.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Surgery |
| 12.3.2.Chemotherapy |
| 12.3.3.High-Dose Chemotherapy with Stem Cell Support |
| 12.3.4.Monoclonal Antibody Treatment |
| 12.3.5.Radiotherapy |
| 12.3.6.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Neuroblastoma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Diagnostics Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.MIBG Scan |
| 13.1.2.Imaging |
| 13.1.3.Urine Analysis |
| 13.1.4.Biopsy |
| 13.2. Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Crizotinib |
| 13.2.2.Doxorubicin Hydrochloride |
| 13.2.3.Cyclophosphamide |
| 13.2.4.Vincristine Sulfate |
| 13.2.5.Others |
| 13.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Surgery |
| 13.3.2.Chemotherapy |
| 13.3.3.High-Dose Chemotherapy with Stem Cell Support |
| 13.3.4.Monoclonal Antibody Treatment |
| 13.3.5.Radiotherapy |
| 13.3.6.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Bristol-Myers Squibb |
| 14.2.2.Johnson & Johnson |
| 14.2.3.Pfizer |
| 14.2.4.Teva Pharmaceutical |
| 14.2.5.United Therapeutics |
| 14.2.6.Amneal Pharmaceuticals, Inc. |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.